Banco Santander’s Takeda Pharmaceutical TAK Stock Holding History

Banco Santander’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,870	Closed	-$179K	–	433
2023 Q1	$179K	Buy	+10,870	New	+$173K	﹤0.01%	347

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Banco Santander's TAK Position: Q2 2023 in Review

Banco Santander sold out of Takeda Pharmaceutical (TAK) in Q2 2023, closing a stake of 10,870 shares — an estimated $179K sold.

Banco Santander first reported a position in TAK in Q1 2023 and held it in 1 quarter. The position peaked at $179K in Q1 2023. 310 funds tracked by Wall St. Rank hold TAK as of Q2 2023.

Banco Santander reported no remaining Takeda Pharmaceutical position as of Q2 2023 after selling out during the quarter.
Banco Santander sold 10,870 Takeda Pharmaceutical shares in Q2 2023, an estimated $179K.
Banco Santander first reported a position in Takeda Pharmaceutical in Q1 2023 and held it in 1 quarter.
Banco Santander's Takeda Pharmaceutical position peaked at $179K in Q1 2023.
310 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2023.

Based on Banco Santander's 13F filing for Q2 2023, filed 14 Aug 2023.